ISIN | LU0255977372 |
---|---|
Valor Number | 2564942 |
Bloomberg Global ID | BBG000Q7HD80 |
Fund Name | Pictet-Biotech -I EUR |
Fund Provider |
Pictet Asset Management S.A.
Genève, Switzerland Phone: +41 58 323 10 24 www.assetmanagement.pictet |
Fund Provider | Pictet Asset Management S.A. |
Representative in Switzerland |
Pictet Asset Management S.A. Genève 73 Phone: +41 58 323 30 00 |
Distributor(s) |
Credit Suisse AG Zürich Phone: +41 44 333 11 11 UBS AG Zürich Phone: +41 44 234 11 11 Vontobel Fonds Services AG Zürich Phone: +41 58 283 74 77 |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The fund seeks to increase the value of your investment while seeking to achieve a positive social impact. The Fund applies a sustainable strategy and invests at least two-thirds of its net assets in equities or similar securities issued by biopharmaceutical companies throughout the world. Companies supporting the health of people with high innovation capacity. Better therapies can deliver true value to patients and healthcare systems alike. These companies are tackling high unmet medical needs and reduce the pressures on healthcare budgets through the reduction of hospital admissions or symptom management. The Fund invests mainly in companies whose significant proportion of their activities are related to, but not limited to, new mechanisms of actions offering potential cures or management of diseases that were hard to treat before, technology platforms, research tools and services in the biotechnology value chain as well as the improvement of therapies or drugs. |
Peculiarities |
Current Price * | 1,163.56 EUR | 06.10.2025 |
---|---|---|
Previous Price * | 1,145.70 EUR | 03.10.2025 |
52 Week High * | 1,175.95 EUR | 11.11.2024 |
52 Week Low * | 751.65 EUR | 09.04.2025 |
NAV * | 1,163.56 EUR | 06.10.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 1,265,175,242 | |
Unit/Share Assets *** | 98,975,710 | |
Trading Information SIX |
YTD Performance | +12.75% |
31.12.2024 - 06.10.2025
31.12.2024 06.10.2025 |
---|---|---|
YTD Performance (in CHF) | +12.04% |
31.12.2024 - 06.10.2025
31.12.2024 06.10.2025 |
1 month | +9.53% |
08.09.2025 - 06.10.2025
08.09.2025 06.10.2025 |
3 months | +30.46% |
07.07.2025 - 06.10.2025
07.07.2025 06.10.2025 |
6 months | +47.18% |
07.04.2025 - 06.10.2025
07.04.2025 06.10.2025 |
1 year | +11.45% |
07.10.2024 - 06.10.2025
07.10.2024 06.10.2025 |
2 years | +38.42% |
06.10.2023 - 06.10.2025
06.10.2023 06.10.2025 |
3 years | +23.34% |
06.10.2022 - 06.10.2025
06.10.2022 06.10.2025 |
5 years | +20.01% |
06.10.2020 - 06.10.2025
06.10.2020 06.10.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | 0.1827 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date | 06.10.2025 |
Insmed Inc | 4.56% | |
---|---|---|
argenx SE ADR | 4.26% | |
Alnylam Pharmaceuticals Inc | 3.96% | |
Neurocrine Biosciences Inc | 3.70% | |
Regeneron Pharmaceuticals Inc | 3.65% | |
Amgen Inc | 3.25% | |
Madrigal Pharmaceuticals Inc | 3.18% | |
Rhythm Pharmaceuticals Inc | 2.86% | |
Gilead Sciences Inc | 2.86% | |
United Therapeutics Corp | 2.84% | |
Last data update | 31.08.2025 |
TER *** | 1.10% |
---|---|
TER date *** | 31.03.2025 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.20% |
Ongoing Charges *** | 1.10% |
SRRI ***
|
|
SRRI date *** | 30.09.2025 |